Please use this identifier to cite or link to this item:
|Title:||Effect of etonogestrel subdermal contraceptive implant (Implanon®) on liver function tests - A randomized comparative study with Norplant® implants|
|Authors:||Biswas, A. |
|Source:||Biswas, A., Viegas, O.A.C. (2004). Effect of etonogestrel subdermal contraceptive implant (Implanon®) on liver function tests - A randomized comparative study with Norplant® implants. Contraception 70 (5) : 379-382. ScholarBank@NUS Repository. https://doi.org/10.1016/j.contraception.2004.05.011|
|Abstract:||The study aimed to assess the possible differences in effects of Implanon® and Norplant® implants on liver function over 2 years of use. This is a 2-year open randomized study of 80 implant (Implanon® and Norplant®) acceptors. Selected parameters of liver function were tested in the serum before implant insertion and at 6, 12 and 24 months after implant insertion. In both the implant groups, the mean total and unconjugated bilirubin and the gamma-glutaryl transferase levels were significantly raised during implant use. For none of the subjects, at any sampling period, did the levels exceed the normal range in our population. There was no significant elevation of any other liver enzymes in either group. It appears that there may be mild hepatocellular dysfunction associated with the use of both Implanon® and Norplant®, which is possibly of no clinical significance to the healthy acceptor. © 2004 Elsevier Inc. All rights reserved.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 15, 2018
WEB OF SCIENCETM
checked on Feb 5, 2018
checked on Feb 19, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.